Stock Financial Ratios, Dividends, Split History

QEP / QEP Resources, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price12.41
Volume2,528,700.00
Market Cap ($M)2,926.19
Enterprise Value ($M)5,410.44
Book Value ($M)3,696.70
Book Value / Share15.55
Price / Book0.80
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 240,968,931
Weighted Average Number Of Shares Outstanding Basic 240,600,000
Weighted Average Number Of Diluted Shares Outstanding 240,600,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.04
Return on Equity (ROE)0.08
Balance Sheet (mrq) ($M)
Assets7,608.60
Liabilities3,911.90
Quick Ration/a
Current Ratio0.24
Income Statement (mra) ($M)
Natural Gas Midstream Revenue111,900,000.00
Revenue From Purchased Oil And Gas0.00
Refining And Marketing Revenue62,600,000.00
Oil And Gas Revenue1,622,900,000.00
Results Of Operations Revenue From Oil And Gas Producing Activities1,548,100,000.00
Natural Gas Production Revenue494,000,000.00
Exploration And Production Revenue0.00
Gas Gathering Transportation Marketing And Processing Revenue15,000,000.00
Oil And Condensate Revenue939,400,000.00
Operating Income101.50
Net Income269.30
Earnings Per Share Diluted1.12
Earnings Per Share Basic1.12
Cash Flow Statement (mra) ($M)
Cash From Operations598.40
Cash from Investing-1,168.00
Cash from Financing598.40
Identifiers and Descriptors
CUSIP74733V100
Central Index Key (CIK)1108827
Related CUSIPS
74733V900 74733V950

Split History

Stock splits are used by QEP Resources, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

VIX + Quants

3h seekingalpha
Picture a VIX trader in your head. What do you see? The perception out there is that VIX traders are typically cowboys-swinging for the fences a la Mr. 50 cent or turning a small stake into millions like the financial space's most famous Target Manager. The perception is that the trader is as volatile as the market. But we found that to be about as far from the truth as you can get when it comes to professional VIX traders.

Zacks.com featured highlights include: ConocoPhillips, Archer Daniels, CVS, Fortinet and Avnet

2018-07-18 zacks
Chicago, IL – July 18, 2018 - Stocks in this week’s article ConocoPhillips (COP - Free Report) , Archer Daniels Midland Company (ADM - Free Report) , CVS Health Corp. (CVS - Free Report) , Fortinet Inc. (FTNT - Free Report) and Avnet, Inc. (AVT - Free Report) . (15-0)

Zacks.com featured highlights include: Integer Holdings, Louisiana-Pacific, Knight-Swift, Herc and Eaton

2018-07-18 zacks
Chicago, IL – July 18, 2018 - Stocks in this week’s article Integer Holdings Corp. (ITGR - Free Report) , Louisiana-Pacific Corp. (LPX - Free Report) , Knight-Swift Transportation Holdings Inc. (KNX - Free Report) , Herc Holdings Inc. (HRI - Free Report) and Eaton Corporation plc (ETN - Free Report) .

Zacks Investment Ideas feature highlights: Herbalife, Questcor and Tesla

2018-07-18 zacks
Chicago, IL – July 18, 2018 – Today, Zacks Investment Ideas feature highlights Features: Herbalife (HLF - Free Report) , Questcor QCOR and Tesla (TSLA - Free Report) . (1-0)

Zacks Industry Outlook Highlights: Norbord, Louisiana-Pacific, Trex and Weyerhaeuser

2018-07-18 zacks
Chicago, IL – July 18, 2018 – Today, Zacks Equity Research discusses Manufacturing - Tools, including Norbord Inc. (OSB - Free Report) , Louisiana-Pacific Corp. (LPX - Free Report) , Trex Company Inc. (TREX - Free Report) and Weyerhaeuser Company (WY - Free Report) . (6-0)

CUSIP: 74733V100